1. Home
  2. HUN vs DNLI Comparison

HUN vs DNLI Comparison

Compare HUN & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HUN
  • DNLI
  • Stock Information
  • Founded
  • HUN 1970
  • DNLI 2013
  • Country
  • HUN United States
  • DNLI United States
  • Employees
  • HUN N/A
  • DNLI N/A
  • Industry
  • HUN Major Chemicals
  • DNLI Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HUN Industrials
  • DNLI Health Care
  • Exchange
  • HUN Nasdaq
  • DNLI Nasdaq
  • Market Cap
  • HUN 2.4B
  • DNLI 2.1B
  • IPO Year
  • HUN 2005
  • DNLI 2017
  • Fundamental
  • Price
  • HUN $10.28
  • DNLI $13.89
  • Analyst Decision
  • HUN Hold
  • DNLI Strong Buy
  • Analyst Count
  • HUN 9
  • DNLI 15
  • Target Price
  • HUN $15.00
  • DNLI $33.85
  • AVG Volume (30 Days)
  • HUN 3.4M
  • DNLI 1.6M
  • Earning Date
  • HUN 08-04-2025
  • DNLI 07-31-2025
  • Dividend Yield
  • HUN 9.73%
  • DNLI N/A
  • EPS Growth
  • HUN N/A
  • DNLI N/A
  • EPS
  • HUN N/A
  • DNLI N/A
  • Revenue
  • HUN $5,976,000,000.00
  • DNLI N/A
  • Revenue This Year
  • HUN N/A
  • DNLI N/A
  • Revenue Next Year
  • HUN $5.10
  • DNLI $335.74
  • P/E Ratio
  • HUN N/A
  • DNLI N/A
  • Revenue Growth
  • HUN 0.02
  • DNLI N/A
  • 52 Week Low
  • HUN $10.25
  • DNLI $10.57
  • 52 Week High
  • HUN $25.12
  • DNLI $33.33
  • Technical
  • Relative Strength Index (RSI)
  • HUN 32.32
  • DNLI 45.02
  • Support Level
  • HUN $11.27
  • DNLI $14.19
  • Resistance Level
  • HUN $12.28
  • DNLI $14.88
  • Average True Range (ATR)
  • HUN 0.41
  • DNLI 0.77
  • MACD
  • HUN -0.07
  • DNLI -0.03
  • Stochastic Oscillator
  • HUN 1.72
  • DNLI 34.55

About HUN Huntsman Corporation

Huntsman Corp is a USA-based manufacturer of differentiated organic chemical products. Its product portfolio comprises Methyl diphenyl diisocyanate (MDI), Amines, Maleic anhydride, and Epoxy-based polymer formulations. The company's products are used in adhesives, aerospace, automotive, and construction products, among others. Its operating segments are Polyurethanes, Performance Products, and Advanced Materials. It derives the majority of its revenue from the Polyurethanes segment,t which includes MDI, polyols, TPU (thermoplastic polyurethane), and other polyurethane-related products. Its geographical segments are the United States & Canada, Europe, Asia-Pacific, and the Rest of the world.

About DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Share on Social Networks: